Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation (NASDAQ: XOMA) operates as a biotechnology-focused royalty aggregator, providing non-dilutive funding to advance therapeutic development. This page serves as the definitive source for official company announcements and third-party analysis of XOMA's strategic partnerships, licensing agreements, and portfolio developments.
Investors and industry observers will find curated updates on milestone achievements, regulatory progress, and financial disclosures. Our aggregation includes press releases related to royalty acquisitions, clinical trial advancements, and commercial partnerships across XOMA's portfolio of innovative therapies.
The resource is particularly valuable for tracking payments tied to licensed assets in therapeutic areas including oncology and rare diseases. Users can expect updates on key business activities while avoiding promotional content or speculative analysis.
Bookmark this page for streamlined access to XOMA's latest developments. Combine regular visits with SEC filings and market data for comprehensive investment research.
XOMA (NASDAQ: XOMA) announced an $8.1 million milestone payment from Viracta Therapeutics. This is linked to Day One Biopharmaceuticals' sale of its Priority Review Voucher (PRV) for $108 million. OJEMDA™, the only approved therapy for relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG), has contributed to this milestone. XOMA's CEO, Owen Hughes, highlighted that the milestone has more than covered their initial $13.5 million investment made in March 2021. They expect future royalties from OJEMDA™ to enhance their royalty portfolio and generate sustainable cash flow.
LadRx (OTCQB: LADX) and ImmunityBio have agreed to mutually terminate the aldoxorubicin license, returning control of the drug to LadRx. This move follows LadRx's 2023 transfer of royalty and milestone rights of aldoxorubicin to XOMA for $5 million upfront, potentially up to $7 million more in milestones. XOMA has consented to the termination and will receive a low-single-digit synthetic royalty on aldoxorubicin and a mid-single-digit percentage from future out-license agreements. Aldoxorubicin, part of LadRx's LADR-based drug program, has shown promise in clinical trials with lower cardiotoxicity compared to doxorubicin. LadRx plans to review aldoxorubicin's data for further clinical development and expects to file an IND for another drug, LADR-7, by late 2024.
XOMA , a biotech royalty aggregator listed on NASDAQ under the symbol 'XOMA', announced its participation in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference. The event will take place at NASDAQ in New York on May 20, 2024.
CEO Owen Hughes and CIO Brad Sitko will represent XOMA in a fireside chat scheduled for 11:00 AM ET. The presentation can be accessed online via a provided link, and replays will be available on XOMA's investor relations website for 90 days post-event.
XOMA reported its first quarter 2024 financial results, earning a $9 million milestone with the FDA approval of OJEMDA™, gaining $9.5 million from Kinnate acquisition, expanding its portfolio, and initiating a $50 million stock repurchase program. The company also reported $1.5 million in total revenues for Q1 2024.
XOMA has acquired an economic interest in three women's health assets from Daré Bioscience, Inc., for $22 million upfront. The assets include XACIATO™ (clindamycin phosphate) vaginal gel, Ovaprene®, and Sildenafil Cream. XACIATO™ is FDA-approved for treating bacterial vaginosis, with commercial activities initiated by Organon in 2023. XOMA aims to create additional value for shareholders with these acquisitions.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMA)?
What is the market cap of XOMA Royalty Corporation (XOMA)?
